sinob_ex99-1.htm

Disclaimer

"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:

This presentation contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations or beliefs, including, but not
limited to, statements concerning the Company's operations, financial
performance and condition. For this purpose, statements that are not
statements of historical fact may be deemed to be forward-looking statements.
The Company cautions that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a variety of
important factors, including those discussed in the Company's reports filed with
the Securities and Exchange Commission from time to time. In addition, the
company disclaims any obligation to update any forward-looking statements to
reflect events or circumstances after the date hereof.

No securities regulatory authority has either approved or disapproved the
contents of this presentation.

Equity Snapshot

* Adjusted to exclude stock option amortization expense

Figures as of April 30, 2010
Symbol:	SNBP.OB
Price:	$0.23
Market Cap:	$27.0 million
Shares Outstanding:	117,587,608
Fiscal Year End	May 31
Fiscal 2009 Revenue:	$3.85 million
Fiscal 2009 Net Income:*	$0.76 million
Projected Fiscal 2010 Revenue:	$7.7 million
Projected Fiscal 2010 Net Income:	$3.5 million

Investment Highlights

Profitable, Fast Growing Chinese Specialty Pharmaceutical Company

Multiple commercialized and pipeline products in muscle relaxant and cardiovascular
markets drive sustainable revenue and profit growth

Fiscal 2010 guidance (fiscal year ending May 2010)

$7.7m revenues (103% revenue increase over prior year)

$3.5m net income, $0.03 EPS

High Margin Commercial Business

Lead product KuTai uniquely differentiated as only muscle relaxant stored at room temperature

Current gross margin above 70% and net margin above 40%

Expected sales of $7.3 million in fiscal 2010 (100% increase over prior year)

Strong YiTai product launch in the cardiovascular ACE inhibitor market

Market exclusivity and price premium as first-to-market product

Expected sales of $4 million in fiscal 2011 (launched in fiscal Q3:2010)

Robust Product Pipeline

Commercializing two new products in current year: cardiovascular and parenteral nutrition

Six additional drugs under development

Corporate Overview

A fully integrated specialty pharmaceutical
company established in 2004 in Nantong,
Jiangsu. Headquartered in Nanjing, Jiangsu.
Listed on OTCBB in 2008.

Specializing in muscle relaxant and
cardiovascular drugs; each category has
total global market of more than $1 billion.

Four marketed products and six major new products in pipeline planned for
commercialization.

SFDA GMP-certified production facilities and established distribution network.

Competitive Advantages

Expanding in fast-growing Chinese healthcare market

Government support includes no-interest loan, tax advantages for five years, and

high-tech corporation benefits

Strong R&D team lead by our Chairman & CEO Dr. Lee Huang, who headed

research team at Bayer Pharmaceutical (USA) for more than 12 years

Proprietary technology enables low cost, high quality API and innovative

formulations for unstable drugs

Experience with Chinese FDA expedites fast approval of first-to-market (FTM) drugs

China Market Opportunity

Population of 1.3 billion consumers with increasing disposable incomes

Chinese government will spend RMB124 billion in the next three years on healthcare
reform

China’s entire drug market estimated at $122B in 2008; projected to be the 5th
largest pharmaceutical market by 2010 and the largest by 2050

Expanding government-backed healthcare policies and reimbursement systems

Growing elderly population is accelerating demand for drugs for seniors

11% of population is over 60 years old; to reach approximately 30% by 2045

Drug Selection Criteria

Development

Commercialization

Distribution →Increasing Market Share

Established networks, Sales infrastructure expansion

>$1B global sales

High-incidence,
high-mortality
diseases

Potential market
exclusivity

New drugs

First-to-market
branded generic and
innovative drugs

Experience with

SFDA process

GMP certified
manufacturing
lines

Launch/marketing
expertise

High margin/low
cost provider

Market for Muscle Relaxants

Muscle relaxants used in major surgery with anesthesia and pain suppression

Total Chinese muscle relaxant market has 25% CAGR due to increase in

general anesthesia surgeries

Total market value in China is over RMB 1 billion (~$130 million)

Four main types of muscle relaxants in use; KuTai (Cisatracurium) has the fewest

and mildest side effects

Market numbers demonstrate Cisatracurium category is rapidly replacing other

muscle relaxants; will soon lead all muscle relaxants currently in use

Two Competitors (Jingsu Hengrui & GSK); both have lower sales; KuTai is the

leader in Cisatracurium category for total sales

Our Product -KuTai

Launched in 2007, KuTai is sales leader in
Cisatracurium category in Chinese market

World’s first to be stored at room temperature;
convenient for surgeons

Safer, more stable and more effective than
other relaxants

Much lower cost in China compared to Nimbex,
made by GSK

Sales revenue from KuTai was $3.6 million in FY
2009 and $1.4 million in FY 2008; an increase of
157%

Expected sales revenue in FY 2010 is $7.3
million, an increase of 100%

Market for Cardiovascular Drugs

Cardiovascular (CV) disease is leading cause of death in the U.S.

Causes an estimated 17.5 million deaths globally every year; about one third

of total annual deaths

According to American Decision Resources research, total Chinese market in

2010 for cardiovascular drug is $800 million

Multiple drugs for treatment of cardiovascular disease in Chinese market;

effectiveness varies by patient types

Main competitor in Chinese market is Acertil from French company Servier

Our Product --YiTai

Launched in third quarter of FY 2010,

estimated sales for FY 2011 is $4 million

A first-to-market drug for which SNBP
enjoys market exclusivity

Chinese health insurance covers drug

For some patients, more effective when taken
with other cardiovascular drugs

Protects blood vessels and kidneys

Extensive Distribution Network

Established nationwide sales and marketing network through distributors

Sales force covering all regions

Long-term relationships with hospitals and doctors

Distributes products in 30 provinces and

key major cities

For Dong Ying China

Robust Product Pipeline

Eplerenone

• Cardiovascular drug for high blood pressure and vascular disease

• No comparable drug produced and marketed in China

• First company to receive approval for clinical trials

Rocuronium

• Fast-acting, injectable muscle relaxant drug

• Can be used in cocktail with KuTai; recognized by doctors

Gantacurium Chloride

• Ultra short acting, rapid onset muscle relaxant

• New generation drug; not yet produced anywhere

Clevidipine Butyrate

• Rapidly reduces blood pressure; controls blood pressure in patients with

acute hypertension when use of oral therapy is neither feasible nor desirable

Diapeptide

• Promotes more rapid healing of surgical incisions

• SFDA approval secured

• Company’s third “First to Market” drug

Memantine

• Treats symptoms of Alzheimer’s disease

• SFDA approved for Phase II Clinical Trials

R&D Partnerships

Nanjing University

China Pharmaceutical University

Nanjing Medical University

Cornell University

Strong R&D

Top tier R&D team lead by Dr. Lee Huang

Patented technology and production provide highest quality and safety levels

for our products

Long-term cooperative relationships with a number of world class research

institutions and universities in both China and USA

Access to advanced research lab and devices

Modern, Scalable Manufacturing Facilities

3,000 sq. meter SFDA GMP-certified production facilities

Location in Nantong Economic & Technology Development Zone confer

extensive tax benefits

6 GMP-Certified Production Lines of tablet, capsule, injectable, granule,

dry power, and chemical ATPs

50% capacity used at current production levels

($ in thousands)	Feb. 28, 2010 (Q3 FY 2010)	May 31, 2009 (FY 2009)
Cash & Cash Equivalents	$ 790	$ 891
Total Current Assets	$ 3,267	$ 1,692
Total Assets	$ 11,415	$ 5,956
Total Current Liability	$ 2,757	$ 5,179
Owner’s Equity	$ 8,658	$ 777

Balance Sheet Highlights

Income Statement Highlights

($ in thousands)	Q1 FY 2010 (Ends Aug 31, 09)	Q2 FY 2010 (Ends Nov. 30, 09)	Q3 FY 2010 (Ends Feb. 28, 10)	Nine Months of FY 2010 (Ends Feb. 28, 10)
Revenue	$ 1,293	$ 2,137	$ 1,993	$ 5,425
Gross Income	$ 963	$ 1,720	$ 1,612	$ 4,295
Gross Margin	74%	80%	81%	79%
Operating expenses	$ 671	$ 596	$ 593	$ 1,860
Operating Income	$ 292	$ 1,124	$ 1,019	$ 2,435
Net Income	$ 237	$ 1,074	$ 941	$ 2,252
Net Margin	18%	50%	47%	42%

Short, Medium and Long-Term Growth Strategy

Leverage patented technology for fast, low-cost drug synthesis

and new drug formulation

Short-term focus on launching high margin, new drugs to Chinese

and other large markets

Medium-term focus on exporting API to U.S. market

Long-term focus on applying the technology platform to identify candidate
compounds from Traditional Chinese Medicines

Become the “Chinese Teva Pharma”

Experienced Management Team

Lee Huang, Ph. D Chairman & Chief Executive Officer

More than 12 years research and managerial experience at Bayer Pharmaceutical, USA

Published more than 30 peer-reviewed articles in scientific journals

Holds numerous patents

Earned Ph.D. in Chemistry, Iowa State University, 1987; B.S. Organic Chemistry, Nanjing University, 1981

James Mu, CPA Director & Chief Financial Officer

Director of China Infrastructure Investment Corporation (Nasdaq: CIIC)

Former Chief Financial Officer of Jingwei International Limited (OTCBB: JNGW.OB)

B.S. Hebei University of Science and Technology (Chemical Engineering)

M.B.A. Baruch College, City University of New York

Xuejun Chen Director & Vice President

Former Vice-President of sales at Nanjing Langkun Medicine Co., Ltd.

Marketing Director of Jiangsu Province for both Xiamen Beidazhilu Biotech Co., Ltd. and Shanxi Dongshen

Medicine Co., Ltd.

M.B.A. Nanjing University, 2007; B.S. Lanzhou University

Attractive Valuation

Peer Group Analysis

Sinobiopharma (SNBP-OCT:BB)

Company Name and Symbol	Price Per Share*	Market Cap*	P/E Forward 12 Months	Est. Revenue Growth	Price/Sales Estimate (2011)*
Sinobiopharma (SNBP-OTC:BB)	$ 0.24	$ 28.2M	4.8	71%	2.07
Wuxi Pahrmaceutical (WX-NYSE)	$ 17.24	$1,200.5M	18.2	22%	4.06
Sinovac Biotech (SVA-NASDAQ)	$ 3.96	$ 214.6M	8.5	-17%	2.62
China Sky One Medical (CSKI-NASDAQ)	$ 12.50	$ 210.9M	6.1	31%	1.59
China Pharma Holdings (CPHI-NYSE AMEX)	$ 2.82	$ 122.1M	5.3	8%	1.90

*Market Data as of 5/26/10

Investment Summary

Profitable, Fast Growing Specialty Pharmaceutical Company

High Margin Business with Robust Market Opportunities

Strong R & D Creating Rich Product Pipeline

Scalable Production Capacity

Nationwide Distribution Network

Solid Fundamentals

Multiple Competitive Advantages

Extensive Industry Relationships

Attractive Valuation

Experienced management Team that can Execute a Comprehensive

Multi-tier Growth Strategy

Contact Information

Transfer Agent

Empire Stock Transfer Inc.

1859 Whitney Mesa Dr.

Henderson, NV 89014

Auditors

Bernstein & Pinchuk LLP

New York Office

Seven Penn Plaza

Suite 830

New York, New York 10001

Tel: 212-279-7900

Beijing Office

RM. 610, Tower E1, Oriental Plaza

No.1 East Chang An Avenue

Dong Cheng District

Beijing, China 100738

Tel: 86-10-85187992

Legal Counsel

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, NY 10006

Tel: 212-930-9700

Investor Relations Contact

James Mu, CFO

Tel: 86.25.5806.1579

Email:xjmu@sinobiopharma.com

Thank You!

Sinobiopharma, Inc.

OTC BB: SNBP
Dong Ying (Jiangsu) Pharmaceutical Co., Ltd.
2 Huangpu Road,
Nanjing, Jiangsu Province 210000
People's Republic of China
Tel: 86.25.5806.1579 Fax: 86.25.8320.2848